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Abstract 115 
Background: 116 
Phenotypes of childhood-onset asthma are characterized by distinct trajectories and functional fea-117 
tures. For atopy, definition of phenotypes during childhood is less clear. 118 
Objective: 119 
To define phenotypes of atopic sensitization over the first 6 years of life by a latent class analysis 120 
(LCA) integrating three dimensions of atopy: allergen specificity, time course, and levels of specific 121 
IgE. 122 
Methods: 123 
Phenotypes were defined by LCA in 680 children of the MAS and 766 of the PASTURE birth cohorts 124 
and compared to classical non-disjunctive definitions of seasonal, perennial, and food sensitization 125 
with respect to atopic diseases and lung function. Cytokine levels were measured in PASTURE.  126 
Results: 127 
The LCA classified predominantly by type and multiplicity of sensitization (food versus inhalant), 128 
allergen combinations, and sIgE levels. Latent classes were related to atopic disease manifestations 129 
with higher sensitivity and specificity than the classical definitions. LCA detected in both cohorts con-130 
sistently a distinct group of children with severe atopy characterized by high seasonal sIgE and a 131 
strong propensity for asthma, hay fever, eczema and impaired lung function even in children without 132 
an established asthma diagnosis. Severe atopy was associated with an elevated interleukin-133 
5/interferon-gamma ratio. A path analysis among sensitized children revealed that among all features 134 
of severe atopy only excessive sIgE production early in life impacted on asthma risk. 135 
Conclusions: 136 
LCA revealed a set of benign, symptomatic, and severe atopy phenotypes. The severe phenotype 137 
emerged as a latent condition with signs of a dysbalanced immune response. It determined high asth-138 
ma risk via excessive sIgE production and directly impacted on impaired lung function. 139 
 140 
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Clinical Implications: 141 
Atopic sensitization was classified into benign, symptomatic and severe phenotypes. Severe atopic 142 
children were characterized by a strong propensity for atopic diseases mediated by excessive sIgE 143 
production early in life and poor lung function even in those without an established asthma diagnosis. 144 
 145 
Capsule summary: 146 
Atopic sensitization was classified with respect to disease relevance in three phenotypes of benign, 147 
symptomatic, and severe atopy, which impacted on asthma risk via excessive production of specific 148 
IgE early in life and on poor lung function. 149 
 150 
Key words: 151 
Atopy; IgE; sensitization; asthma; lung function; cytokines; latent class analysis; unsupervised cluster-152 
ing; path analysis; epidemiology  153 
 154 
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Abbreviation list: 156 
Abbreviations used 157 
IgE: Immunoglobulin E 158 
sIgE: specific Immunoglobulin E 159 
LCA: Latent class analysis 160 
LC: Latent class 161 
MAS: Multizentrische Allergiestudie 162 
PASTURE: Protection against allergy: Study in rural environments 163 
CAP: Carrier polymer system 164 
ISAAC: International Study of Asthma and Allergies in Childhood 165 
AD: Atopic dermatitis 166 
FEV1: Forced expiratory volume in 1 second 167 
ROC: Receiver operating characteristic 168 
AIC: Akaike information criterion 169 
AUC: Area under the ROC curve 170 
IU/ml: International Units/milliliter 171 
ng/ml: Nanogramms/milliliter 172 
µg/ml: Microgramms/milliliter 173 
pg/ml: Picogramms/milliliter 174 
IL-5: Interleukin-5 175 
IFN-γ: Interferon-γ 176 
PI: Phorbol 12-myristate 13-acetate / ionomycin 177 
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Introduction 179 
Asthma and atopy often manifest concomitantly before school-age. But the interrelation of both phe-180 
nomena remains obscure, possibly because both conditions may result from a multitude of individual 181 
pathologies, whose complex interferences blur the entire picture. In the case of asthma, wheezing phe-182 
notypes have been identified and consolidated by data-driven approaches.1-3 These approaches, how-183 
ever, are currently only emerging for atopy classification. 184 
Because of co-sensitizations, categorization by allergen specificity or type of sensitization is ambigu-185 
ous and leads to overlapping groups such as food, inhalant perennial, or inhalant seasonal sensitiza-186 
tion.4 Other approaches applying disjunctive categories mainly rely on temporal patterns, focusing on 187 
the age of onset,5-9 longitudinal trends,10 persistence of IgE sensitization,11,12 or consider multiplicity of 188 
allergen specificities, i.e. mono- versus polyvalent sensitization.13-18 However, it has been pointed out 189 
that all the above approaches are susceptible to investigator bias.19 This issue can be overcome by 190 
data-driven, unsupervised statistical methods such as latent class analysis (LCA). Until now, these 191 
approaches focused on allergen specificities at one20 or several19,21,22 time points, but did not consider 192 
strength of sensitization as assessed by IgE levels. 193 
We considered this omission a shortcoming given the well-known disease relevance of IgE-levels23 194 
and therefore included this dimension in our analysis. We applied LCA to two rather different birth 195 
cohorts, i.e. the urban MAS cohort (Multizentrische Allergiestudie, MAS) and the rural PASTURE 196 
study (Protection against allergy: Study in rural environments). The aim of this analysis was to com-197 
pare LCA-derived classification to classical definitions of atopy based on carrier polymer system 198 
(CAP) classes and to relate both systems to manifestation of asthma, allergic diseases, cytokine ex-199 
pression, and lung function. Finally we sought to integrate the various aspects of atopy in a path model 200 
for asthma and lung function.  201 
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Methods 202 
Study design and population 203 
Both birth cohorts were set up to study the development of childhood asthma and allergies. MAS re-204 
cruited 1314 healthy mature infants born in 1990 in five German cities (Berlin, Düsseldorf, Freiburg, 205 
Mainz, and Munich).24 Of those, 499 had risk factors for atopy, i.e. raised cord blood IgE (≥09 kU/L) 206 
or at least two atopic family members. PASTURE recruited 1133 children in 2002-2005 from rural 207 
areas in 5 European countries: Austria, Finland, France, Germany, and Switzerland.25 Children of 208 
mothers living on family-run livestock farms were assigned to the farm study group. The reference 209 
study group comprised children of mothers from the same rural areas but not living on a farm. Both 210 
studies were approved by the ethics committees of the participating institutions, and written informed 211 
consent was obtained from the children’s parents or guardians. 212 
Atopic sensitization (Specific IgE in serum samples) 213 
In MAS, serum samples were obtained from the children at 1, 2, 3, 5, 6 and 7 years of age. Specific 214 
IgE antibodies (sIgE) to food allergens (cow’s milk, egg white, soy bean, wheat) and inhalant aller-215 
gens (house dust mites Dermatophagoides pteronyssinus, cat dander, mixed grass, birch pollen, and 216 
dog dander from age 3 years on) were determined with ImmunoCAP (Phadia, Freiburg, Germany). 217 
Soy bean was excluded from the analyses because it was not measured in PASTURE for all time 218 
points and dog dander due to the lack of measurements at year 1 and 2. In PASTURE, specific IgE for 219 
6 food and 13 common inhalant allergens was assessed in cord blood samples and at the age of 12, 54 220 
and 72 months in peripheral blood by using the semiquantitative Allergy Screen test panel for atopy 221 
(Mediwiss Analytic, Moers, Germany) in a central laboratory.4 Because of common cross-reactivity 222 
and low frequencies of some specificities, the original 19 specificities were combined into 9 categories 223 
finally entered in the LCA: grass pollen (rye pollen or grass pollen mix), tree pollen (alder, birch pol-224 
len or hazel pollen) cat, dog, mites (Dermatophagoides pteronyssinus or Dermatophagoides farinae), 225 
hen’s egg, cow’s milk, wheat flour, nuts (peanut or hazelnut). In MAS the categories nuts and dog 226 
were not available. 227 
 228 
 229 
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Questionnaires 230 
In MAS, at each follow-up visit at the age of 1, 3, 6, 12, 18, and 24 months and from then on yearly 231 
within 4 weeks of the child’s birthday up to the age of 7 years, parents were interviewed for asthmatic 232 
and atopic symptoms and disease, diet, development, and psychological aspects. From age 5 years 233 
onwards, questions relating to wheeze corresponded to the International Study of Asthma and Aller-234 
gies in Childhood (ISAAC) core questions. In PASTURE, questionnaires were administered at the end 235 
of pregnancy and when the children were 2, 12, 18, 24, 36, 48, 60, and 72 months of age to obtain 236 
information on frequencies of wheeze, parental atopic status, and environmental exposures with a fo-237 
cus on farming and nutrition.4 Variable definitions were harmonized between both studies. Lifetime 238 
asthma was defined as a physician’s diagnosis of asthma at least once per lifetime as reported by the 239 
parents at age 6 years, children with no diagnosis of asthma and no current wheeze in the last 12 240 
months served as controls. Hay fever was defined as parental reported rhinitis symptoms ever or a 241 
physician’s diagnosis of hay fever or allergic rhinitis ever at age 6. Atopic dermatitis (AD) was de-242 
fined as a physician’s diagnosis of atopic eczema at least once per lifetime as reported by the parents 243 
at age 6 years, children with no diagnosis of atopic eczema and no atopic eczema in the last 12 months 244 
where the control subjects. 245 
Lung function measurements 246 
At the age of 7 years in MAS in 801 children,6 and at 6 years in PASTURE in 799 children,3 forced 247 
expiratory volume in 1 second (FEV1) was measured and z-standardized.26 248 
Cytokine assessment 249 
In PASTURE, whole blood supernatants from 6-year-old children were collected after 48h stimulation 250 
with PI (5ng/ml PMA, 1µg/ml Ionomycin). Interleukin (IL)-5 and Interferon (IFN)-γ were measured in 251 
the supernatants by multiplexed cytometric bead array (BD Biosciences, San Jose, CA) in Marburg, 252 
Germany. The detection limit was 0.01pg/ml and values below were replaced by 0.001 in n=17 (IL-5) 253 
and n=11 (IFN-γ) individuals. Cytokine concentrations were standardized to peripheral blood leuko-254 
cyte counts (Sysmex KX-21N blood cell analyzer; Sysmex Corporation, Kobe, Japan) and z-255 
transformed. 256 
Statistical Analysis 257 
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Children with missing sIgE data for at least 3 out of 6 (MAS) or 2 out of 4 (PASTURE) measurement 258 
time points were excluded. For all other children, missing sIgE values were imputed by multiple linear 259 
imputation of the continuous sIgE values in 20 replicates. Categorical variables were created from the 260 
imputed continuous variables for the level of sIgE with following categories (in kU/L): sIgE <0.35; 261 
≥0.35 sIgE <0.7; ≥0.7 sIgE <3.5; sIgE ≥ 3.5 corresponding to CAP classes; in PASTURE the lowest 262 
category was again split at 0.2 kU/L because of the comparably lower sIgE values and a lower detec-263 
tion limit of the measurement method. For each imputed dataset an LCA based on categorized sIgE 264 
values between birth and year 6 was performed assigning individuals to classes by their highest poste-265 
rior probabilities,27 and each subject was assigned to the latent class (LC) it was classified in the ma-266 
jority of the 20 replications (more details see in the methods section of the Online Repository). To 267 
enhance recognition the retrieved LCs were arbitrarily labeled according to their key features. 268 
Classical definitions of atopy were defined as being sensitized to a specific allergen or groups of aller-269 
gens (seasonal, perennial, or food allergens) at a specific CAP class at a specific time point, irrespec-270 
tively of sensitizations to other allergens. The LCs were compared to these classical definitions with 271 
respect to true- and false-positive rates using receiver operating characteristics (ROC) curves. Associa-272 
tions of outcomes with potential determinants were calculated by linear or logistic regression. Effect 273 
estimates are given with 95%-confidence intervals as odds ratios (ORs) for dichotomous outcomes and 274 
β-estimates for linear continuous outcomes such as lung function parameters. All regression analyses 275 
were adjusted for center and in PASTURE additionally for study group. Control subjects used in the 276 
regression models for LCA were subjects assigned to LC “unsensitized” and for classical definitions 277 
children without any sensitization at CAP class 1 at the respective time point. Statistical analyses were 278 
performed with SAS 9.4 and MPLUS 7. 279 
  280 
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Results 281 
The analysis population consisted of 680 MAS children (52% of 1314 at recruitment, Figure 1A) and 282 
766 PASTURE children (68% of 1133, Figure 1B) with complete or imputed sIgE values which did 283 
not differ from the excluded children with respect to sensitization status at any age (Table E1). The 284 
LCA revealed solutions with 3 to 6 classes with the best AIC-values for the 5-class solutions in both 285 
studies (Table E2). The distribution of LCs across study centers was rather homogenous in both stud-286 
ies (Figure E1). 287 
As illustrated by Figure 2, the largest classes containing 71% (MAS) and 54% (PASTURE) of all 288 
children were characterized by absence of sensitization and consequently labeled “unsensitized”. One 289 
MAS class and two PASTURE classes included mainly children with sensitization to food allergens. 290 
The MAS children in the “food” class were predominantly mono-sensitized to cow’s milk or hen's 291 
egg; in PASTURE the larger class was sensitized only to “cow’s milk” and the other class to “food” 292 
allergens beyond cow’s milk. The remaining classes represented mainly inhalant sensitization: In 293 
PASTURE one class included children with sensitization predominantly to either seasonal or perennial 294 
“inhalant” allergens. The corresponding MAS children were grouped into two classes with either sen-295 
sitization to “seasonal” or “mite” allergens. The smallest class within each study was termed “severe 296 
atopy” for its specific features explained below. 297 
A hallmark of LC “severe atopy” was sensitization predominantly to seasonal allergens up to CAP 298 
class 3 with a steep increase in the prevalence of sensitization before year 4 or 5. Food co-sensitization 299 
occurred in the majority of this LC (MAS: 88%; PASTURE: 67%) and mite co-sensitization in a rele-300 
vant proportion (MAS: 31%; PASTURE: 26%) at year 6 and CAP class 2. In the MAS LC “severe 301 
atopy” food co-sensitization was very common already at year 1 (81%, CAP class 2). In PASTURE, 302 
food sensitization at year 1 occurred in 22% when considering a cut-off level of 0.2 kU/L. Taken to-303 
gether, LCA grouped mainly for allergen specificity (food versus inhalant classes), strength of sensiti-304 
zation and partially for temporal patterns. 305 
LCs are mutually exclusive and integrate information across CAP classes and over various time 306 
points, whereas classical definitions of sensitization such as sIgE to any inhalant or any food allergens 307 
can overlap and depend on the underlying CAP class and the time point of measurement. Though both 308 
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systems were comparable at the most suitable time points and CAP cut-off levels as determined by 309 
ROC curves (Figure E2, Table E3), their associations with disease manifestations diverged in several 310 
instances (Figure 3, Figure E3): In both studies, sIgE to any food allergens overestimated the associa-311 
tions with health conditions when compared to the food LCs. Conversely, LC “severe atopy” was 312 
much stronger associated with asthma-related conditions as compared to sIgE against any inhalant 313 
allergens even at CAP class 3. The associations of disease risk with the respective LCs were paralleled 314 
by those of parental atopy (Figure E4). A sensitivity analysis (Figures E5 and E6) revealed that each 315 
of the three dimensions allergen specificity, specific IgE levels, and time course importantly contribut-316 
ed to the composition and disease relevance of the respective LCs. 317 
Based on disease relevance, the LCs were grouped within three atopy phenotypes (Figure 4): LCs 318 
related to food sensitization represented a benign phenotype without any disease relevance, LCs relat-319 
ed to inhalant sensitization corresponded to a symptomatic phenotype with risk of asthma, yet normal 320 
lung function. In contrast, the LC “severe atopy” was characterized by impaired lung function and a 321 
much higher propensity of atopic disease. 322 
To better understand the singular phenomenon of severe atopy and to contrast it with benign and 323 
symptomatic sensitized children we assessed biologically relevant features of atopy. Though the LCA 324 
discriminated well between oligo- and polyvalent sensitization, polyvalence was not specific for se-325 
vere atopy but also characterized “food” sensitization in PASTURE (Figure E7). However, a unique 326 
feature of severe atopy consisted in high levels of specific IgE to inhalant, particularly seasonal, aller-327 
gens (p<0.0001, Figure 5A, Figure E8). This resulted from an excessive increment in sIgE levels in 328 
the first 3-4 years (and a milder trend in subsequent years) as compared to the weak rise in symptomat-329 
ic and benign atopy, particularly for seasonal and food sIgE (p<0.0001, Table 1). Similarly severe 330 
atopy differed from the other LCs with respect to the ratio of IL-5 over IFN-γ expression, thereby re-331 
flecting the activation of T helper (Th) 2 rather than Th1 subsets (p<0.01, Figure 5B). 332 
To elucidate the mutual relation between severe atopy and its various features differentiating it from 333 
the benign and symptomatic phenotypes, we performed a path analysis (Figure 6). In both studies, 334 
asthma was determined by severe atopy via an excessive increment in sIgE to seasonal allergens and 335 
high levels of sIgE at 6 years. Though including only 5% of all children, severe atopy explained 20% 336 
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of all sensitized asthma cases. Early sensitization to food allergens, Th2/Th1-ratio, and poly-337 
sensitization were similarly determined directly or indirectly by severe atopy, but not related to asth-338 
ma. 339 
Similarly as in atopic individuals also in the entire population of both cohorts, the inverse association 340 
of sIgE levels and FEV1 was completely explained by severe atopy (change-in-estimate: 104%) as 341 
held partially true for the association of asthma and FEV1 (change-in-estimate: 38%). This was not 342 
unexpected since severe atopy contained also a substantial proportion of children without current 343 
wheeze or an established asthma diagnosis, but with FEV1 values within the lowest decile (Figure 7). 344 
  345 
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Discussion 346 
Using LCA we classified preschool children for sensitization patterns considering the three dimen-347 
sions allergen specificity, time course and strength of sensitization. The resulting LCs were related to 348 
manifest atopic disease with higher sensitivity and specificity as compared to classical definitions of 349 
sensitization. The food LCs of both cohorts emerged as a benign atopy phenotype without individual 350 
risk and family history of asthma. A symptomatic phenotype was found in the inhalant LCs with sub-351 
stantial risk of atopic diseases, but without impaired lung function. The LC “severe atopy” comprised 352 
children with high sIgE levels to seasonal allergens, much stronger associations with atopic diseases 353 
and low FEV1-values even in those without an established asthma diagnosis. 354 
A major advantage of this analysis was the comprehensive approach covering the first 6 years of life 355 
with detailed information on various major allergen specificities at different levels. Missing values 356 
were successfully imputed thereby providing a complete dataset for 1446 children without observable 357 
selection from the originally recruited populations. A further strength was the replication of the main 358 
findings in two rather different birth cohorts. 359 
Admittedly, not all LCs were fully congruent between the studies: the LC with mono-sensitization to 360 
“cow’s milk” at low sIgE levels was specific for PASTURE and might be explained by the rather 361 
common consumption of cow’s milk in this rural population. Correspondingly, in MAS a specific 362 
“mite” class emerged reflecting the relevance of this allergen in an urban cohort. An additional charac-363 
teristic of MAS was the higher proportion of early sensitization to food allergens in LC “severe atopy” 364 
possibly resulting from the recruitment focus on children with elevated sIgE levels in cord blood. 365 
Nevertheless these peculiarities do not interfere with the core results of this analysis. 366 
The role of specific IgE in the manifestation of atopic diseases has long been discussed controversial-367 
ly. In 1989, Burrows and colleagues suggested a linear relation between total IgE levels and asthma 368 
risk.23 Ten years later, the question arose whether elevated total IgE levels were to some extent deter-369 
mined by specific wheeze phenotypes.8 Soon thereafter, Illi et al. hypothesized that “an underlying 370 
condition drives both a certain pattern of sensitization and the development of childhood asthma.”11 371 
Later-on the concept of multiplicity of sensitizations was introduced as a genuine risk factor for respir-372 
atory allergy.13-19,28 373 
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Against this background of conflicting hypotheses we sought a unifying concept. Without providing 374 
any information on atopic disease, an LCA merely based on time course and levels of sIgE against 375 
food and inhalant allergens yielded a clear trichotomy with respect to manifestation, severity, and fam-376 
ily history of atopic disease in both cohorts. Using classical definitions of atopy such as sIgE to any 377 
food or any seasonal allergens, the respective associations were over- or underestimated, and the sig-378 
nals were diluted. 379 
The detection of an innocent or benign atopy phenotype predominantly related to food sIgE is clinical-380 
ly relevant as it suggests that children with asthma allocated to one of the benign food LCs should not 381 
be considered ‘atopic asthma’ in epidemiologic studies. Rather these children might suffer from non-382 
atopic asthma and concomitantly happen to produce irrelevant food sIgE as do many children without 383 
asthma. 384 
Also the distinction between symptomatic and severe atopy has vast implications: Children with 385 
symptomatic atopy suffer from asthma, hay fever and eczema, though at lower risk and with a less 386 
severe phenotype as suggested by rather normal lung function parameters. 387 
Severe atopy was characterized by specific and also unspecific features: With LC “food” in PASTURE 388 
severe atopy shared polyvalent sensitization to five or more allergens (Figure E7). Children with early 389 
food sensitization were allocated both to severe atopy and to the food LCs with similar absolute 390 
counts, though at different proportions. While early food sensitization might be seen as the first raised 391 
flag of severe atopy, it cannot serve as a specific predictor of this condition among sensitized children. 392 
A unique hallmark of severe atopy, however, was the elevated Th2/Th1 cytokine ratio at the age of 6 393 
years (Figure 5B). This emerging dysbalance may result from an initial Th2 cell activation without 394 
subsequent resolution into “protective immunologic tolerance’’ as suggested by Rowe et al.29 Besides 395 
the specifically strong association with impaired lung function, severe atopy harbored a relevant pro-396 
portion of children with FEV1 values in the lowest decile but without an established asthma diagnosis. 397 
In practical terms, this group of children might benefit from further clinical work-up and careful moni-398 
toring of sIgE increment within the first 3-4 years. 399 
A further exclusive feature of severe atopy was found in high sIgE levels, which followed a steep rise 400 
in seasonal sensitization particularly before age 3-4. This sharp increase was the only relevant longitu-401 
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dinal variation among the LCs and distinguished the current LCA for atopy from an earlier LCA for 402 
wheeze.3 This earlier LCA was entirely determined by the time course of symptoms and produced a 403 
late-onset wheeze phenotype emerging only beyond age 3-4 years with strong associations to atopic 404 
sensitization, particularly severe atopy (Figure E3). In this context it is noteworthy that the steep in-405 
crease in sIgE levels within severe atopy preceded the first symptoms of the atopic late-onset wheeze 406 
phenotype. This temporal relationship in combination with the strength and specificity of the associa-407 
tion of severe atopy with asthma and impaired lung function and the consistency of the findings be-408 
tween both studies argues in favor of a causal relationship. 409 
To corroborate this assumption we performed a path analysis contrasting severe atopy with benign and 410 
symptomatic atopy in regard to the above features. According to this analysis the effect of severe ato-411 
py on asthma was completely mediated through the steep increase in sIgE and the resulting high sIgE 412 
levels. As this steep increase was seen for all sIgE specificities in severe atopy (Table 1), one may 413 
hypothesize that excessive sIgE production is a generic phenomenon beyond any specific allergen. 414 
This crucial role of uncontrolled sIgE production is indirectly supported by evidence from clinical 415 
studies showing an alleviating effect on childhood asthma symptoms by neutralizing sIgE with an anti-416 
IgE antibody.30,31 Reversely, the pathway model may provide a suitable explanation for the efficacy of 417 
anti-IgE treatment. Additionally severe atopy, or in practical terms a steep increase in sIgE until age 3-418 
4, may serve as a selection criterion for children susceptible to anti-IgE therapy. As severe atopy ex-419 
plains at least every fifth case of atopic asthma a relevant share may profit from this therapeutic ap-420 
proach. 421 
Moreover, severe atopy directly determined low FEV1 values and explained the inverse association of 422 
FEV1 and asthma, ultimately implying that poor lung function at age 6 years is not a feature of asthma 423 
unless it is related to severe atopy. In other words, poor lung function and excessive production of 424 
sIgE might result from the same latent phenomenon. This shared pathogenesis may point towards a 425 
local process of uncontrolled production of sIgE in the bronchial mucosa32, which again might be the 426 
target of future interventions. 427 
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The other features of severe atopy, i.e. early food sensitization, an elevated Th2/Th1-ratio, and poly-428 
sensitization emerged from the path analysis as epiphenomena without any proper effects on asthma 429 
risk. Rather they might hint at an authentic latent phenomenon, which manifests with many faces. 430 
 431 
Integrating temporal patterns, allergen specificity and strength of sensitization in a data-driven ap-432 
proach we found three phenotypes of atopy with respect to disease-relevance. In contrast to benign and 433 
symptomatic atopy, severe atopy identified a circumscribed group of children with high sIgE values, 434 
pronounced disease risk, and poor lung function. Severe atopy as a latent phenomenon may thus corre-435 
spond to the condition underlying both childhood asthma and sensitization patterns as previously pos-436 
tulated by Illi et al.11 The path analysis performed in atopic individuals now suggests a link between 437 
severe atopy and asthma via excessive sIgE production particularly to seasonal allergens early in life 438 
and may direct further research into the biologic fundamentals of atopy. 439 
 440 
 441 
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Tables 
Table 1: Increment in sIgE production comparing severe atopy to the other atopy phenotypes 
Time period Study Seasonal sIgE Food sIgE Perennial sIgE 
  ß      (95% CI) P ß      (95% CI) P ß      (95% CI) P 
Early increase        
Year 0 – Year 1 PASTURE 0.05 (-0.28 - 0.39) 0.7491 0.69 (0.12 – 1.25) 0.0175 0.30 (-0.50 - 1.09) 0.4653 
Year 1 – Year 3 MAS 4.28 (2.97 – 5.60) <.0001 3.29 (1.93 – 4.66) <.0001 0.62 (-0.78 – 2.02) 0.3843 
Year 1 – Year 4 PASTURE 7.25 (6.32 – 8.18) <.0001 2.45 (1.55 – 3.35) <.0001 1.29 (0.22 – 2.37) 0.0187 
Late increase        
Year 3 – Year 6 MAS 2.47 (0.84 – 4.10) 0.0030 3.78 (2.47 - 5.09) <.0001 1.44 (0.01 – 2.87) 0.0483 
Year 4 – Year 6 PASTURE 1.21 (-0.01 - 2.43) 0.0524 -0.27 (-1.09 – 0.55) 0.5193 1.06 (0.11 – 2.00) 0.0290 
Overall increase        
Year 1 – Year 6 MAS 5.01 (3.33 – 6.68) <.0001 4.65 (3.23 – 6.07) <.0001 2.03 (0.09 – 3.97) 0.0404 
Year 1 – Year 6 PASTURE 6.13 (4.99 – 7.27) <.0001 1.17 (0.21 - 2.12) 0.0163 1.79 (0.66 - 2.92) 0.0018 
 
The beta estimates result from linear regression of the log-transformed sIgE values on severe atopy vs. the other two atopy phenotypes within the respective time 
period, adjusted for baseline sIgE values. The estimates remained stable after mutual adjustment for incremental increase of the other specificities. 
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Figure Legends 
Figure 1: Selection of study populations 
 
Figure 2: Latent classes of atopy as characterized by allergen-specificity, time course, and levels 
of specific IgE 
 
Figure 3: Associations of asthma-related conditions with latent classes and classical definitions of 
atopic sensitization at age 6 
 
* As there was no case of lifetime asthma in this LC, we calculated a conservative estimation of the 
odds ratio based on one case of asthma in this LC, which was simulated at random. Black point esti-
mates with error bars mark the latent classes as reference, red the classical definitions as comparison. 
 
Figure 4: Atopy phenotypes in relation to the distribution of latent classes in both populations 
 
Figure 5: Absolute sIgE levels and ratio of IL-5 to IFN-γ expression at age 6 
 
Figure 6: Path diagram comparing severe atopy to the other atopy phenotypes, including its fea-
tures, lung function, and asthma in both populations 
 
Significant associations are shown by solid arrows. Absent associations are represented by interrupted 
dotted arrows. The values represent the association estimates from the final model including signifi-
cant paths only. 
 
Figure 7: Proportion of non-asthmatic children with reduced lung function by latent classes 
 
Reduced lung function was defined as values in the lowest decile of the FEV1 distribution. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Online Repository 
 
Latent class analysis reveals clinically relevant atopy phenotypes in two 
birth cohorts 
 
Alexander J. Hose, MA, MPH1; Martin Depner, PhD1, Sabina Illi, PhD1, Susanne Lau, MD, PhD2, 
Thomas Keil, MD, MScPH3,4, Ulrich Wahn, MD2, Oliver Fuchs, MD, PhD5,6,7, Petra Ina Pfefferle, 
PhD, DrPH8, Elisabeth Schmaußer-Hechfellner, BSc1, Jon Genuneit, MD9, Roger Lauener, MD10,11, 
Anne M. Karvonen, PhD12, Caroline Roduit, MD10,13, Jean-Charles Dalphin, MD, PhD14, Josef 
Riedler, MD15, Juha Pekkanen, MD, PhD12,16, Erika von Mutius5, MD; Markus J. Ege5, MD, and the 
MAS and PASTURE study groups 
 
 
MAS study group members: 
Carl Peter Bauer17, Johannes Forster18, Fred Zepp19, Volker Wahn20, Antje Schuster21, Renate L. 
Bergmann22, Karl E. Bergmann22, Andreas Reich23, Linus Grabenhenrich23 
 
PASTURE study group members: 
Bianca Schaub5, Georg J. Loss1,24, Harald Renz25, Michael Kabesch26,27, Marjut Roponen28, Anne 
Hyvärinen12, Pekka Tiittanen12, Sami Remes29, Charlotte Braun-Fahrländer30,31, Remo Frei10,32, 
Vincent Kaulek14, Marie-Laure Dalphin33, Gert Doekes34, Nicole Blümer35, Urs Frey7 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1Dr. von Hauner Children’s Hospital, Ludwig-Maximilians-University of Munich, Lindwurmstr. 4, D-
80337, Munich, Germany 
2Department for Pediatric Pneumology and Immunology, Charité–Universitätsmedizin Berlin, Berlin, 
Germany 
3Institute of Social Medicine, Epidemiology and Health Economics, Charité–Universitätsmedizin 
Berlin, Berlin, Germany 
4Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Wuerzburg, Germany 
5Dr. von Hauner Children’s Hospital, Ludwig-Maximilians-University of Munich, Lindwurmstr. 4, D-
80337, Munich, Germany, and Comprehensive Pneumology Center, Munich (CPC-M), Germany; 
Member of the German Center for Lung Research (DZL) 
6Division of Respiratory Medicine, Department of Pediatrics, Inselspital, University of Bern, Bern, 
Switzerland 
7University Children’s Hospital (UKBB), University of Basel, Spitalstr. 33, CH-4056 Basel, 
Switzerland 
8Comprehensive Biomaterial Bank Marburg CBBM, Fachbereich Medizin der Philipps Universität 
Marburg, Zentrum für Tumor und Immunbiologie ZTI, Hans-Meerweinstr. 3, D-35043 Marburg, 
Germany; Member of the German Center for Lung Research 
9Ulm University, Institute of Epidemiology and Medical Biometry, Helmholtzstr. 22, D-89081 Ulm, 
Germany 
10Christine Kühne Center for Allergy Research and Education (CK-CARE), Davos, Switzerland 
11Children’s Hospital of Eastern Switzerland, St. Gallen, Switzerland 
12Department of Health Protection, National Institute for Health and Welfare, P.O. Box 95 FIN-70701 
Kuopio, Finland 
13Children's Hospital, University of Zürich, Zürich, Switzerland 
14University of Besançon, Department of Respiratory Disease, UMR/CNRS6249 Chrono-environment, 
University Hospital, 25030 Besançon, France 
15Children's Hospital Schwarzach, Kardinal Schwarzenbergstr. 2-6, A-5620 Schwarzach, Austria, 
Teaching Hospital of Paracelsus Medical Private University Salzburg 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16Department of Public Health, University of Helsinki, Helsinki, Finland 
17Technical University of Munich, Department of Pediatrics, Munich, Germany 
18Department of Paediatrics, St. Josefs Hospital, Freiburg, Germany 
19Centre for Paediatric and Adolescent Medicine, University Medical Centre Mainz, Mainz, Germany 
20University Children’s Hospital, Charité, Berlin, Germany 
21Department of Paediatrics, University Medical Centre Düsseldorf, Düsseldorf, Germany 
22Department of Obstetrics, Charité-Universitätsmedizin Berlin, Berlin, Germany 
23Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin 
Berlin, Berlin, Germany 
24University of California, San Diego, School of Medicine, Department of Pediatrics, 9500 Gilman 
Drive, La Jolla, CA 92093-0831, U.S.A. 
25Department of Clinical Chemistry and Molecular Diagnostics, Philipps University of Marburg, 
Marburg, Germany; Member of the German Center for Lung Research 
26KUNO Children’s University Hospital Regensburg, Department of Pediatric Pneumology and 
Allergy Campus St. Hedwig, Steinmetzstr. 1-3, D-93049 Regensburg, Germany 
27Hannover Medical School, Clinic for Pediatric Pneumology and Neonatology, Carl-Neuberg-Str. 1, 
D-30625 Hannover, Germany 
28Department of Environmental Science, Inhalation Toxicology Laboratory, University of Eastern 
Finland, P.O Box 1627, Kuopio, Finland 
29Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland 
30Swiss Tropical and Public Health Institute, Socinstr. 57, P.O. Box, CH-4002 Basel, Switzerland 
31University of Basel, Petersplatz 1, CH-4003 Basel, Switzerland 
32Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland 
33University of Besançon, Department of Pediatrics, University Hospital, 25030 Besançon, France 
34Utrecht University, Institute for Risk Assessment Sciences (IRAS), Division of Environmental 
Epidemiology, PO Box 80178, 3508TD, Utrecht, Netherlands 
35Department of Clinical Chemistry and Molecular Diagnostics, Philipps University of Marburg, 
Marburg, Germany  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Corresponding author: 
Alexander Hose, MA MPH 
Dr. von Hauner Children’s Hospital 
Ludwig-Maximilians-University of Munich 
Lindwurmstr. 4 
D – 80337 München 
 
Phone:  +49(0)89 – 4400-57993  
Fax:      +49(0)89 – 4400-54452 
E-mail: Alexander.Hose@med.uni-muenchen.de 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Funding (MAS): 
The MAS study was funded by grants from the German Federal Ministry of Education and Research 
(BMBF; reference numbers 07015633, 07 ALE 27, 01EE9405/5, 01EE9406) and the German 
Research Foundation (DFG; reference number KE 1462/2-1). The funders had no role in the design, 
management, data collection, analysis or interpretation of the data or in the writing of the manuscript 
or the decision to submit for publication. 
 
Funding (PASTURE): 
This work has been supported by the European Commission (research grants QLK4-CT-2001-00250, 
FOOD-CT-2006-31708, and KBBE-2007-2-2-06), the European Research Council (Grant 250268), 
and the German Center for Lung Research (DZL). The funding sources did not influence the study 
design; the collection, analysis, and interpretation of data; the writing of the manuscript; and the 
decision to submit the paper for publication. The corresponding author had full access to all of the data 
in this study and takes complete responsibility for the integrity of the data and the accuracy of the data 
analysis. 
 
Acknowledgements (MAS): 
We would like to thank all MAS contributors, especially the PIs of the study centres Carl Peter Bauer 
(Technische Universität München), Johannes Forster (St. Josefs Krankenhaus Freiburg), Walter 
Dorsch, Wolfgang Kamin, Fred Zepp (Mainz University Medical Center), Volker Wahn, Antje 
Schuster (Düsseldorf University Hospital), the co-initiators Karl Bergmann and Renate Bergmann as 
well as Bodo Niggemann, Petra Wagner and Gabi Schulz (Charité - Universitätsmedizin Berlin). 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Methods 
Statistical Analysis 
Multiple imputation was based on continuous sIgE values of at least 4 of 6 time points in MAS (age 1-
7 years) and 3 of 4 time points in PASTURE (age 0-6 years). Multiple linear imputation was 
performed in 20 runs resulting in 20 datasets for each cohort, then the continuous values for each 
dataset were transformed for MAS into 4 (<0.35, <0.7, <3.5, or ≥ 3.5 kU/L), for PASTURE into 5 (one 
additional CAP class <0.2 kU/L) ordinal CAP classes. At this step, data up to age 6 years were used in 
both studies for comparability. Finally, in MAS 35 4-staged variables representing 7 allergen 
specificities at 5 time points and in PASTURE 36 5-staged variables representing 9 allergen 
specificities at 4 time points were entered in the LCAs, which were performed for each of the 20 
imputed dataset per cohort. For each LCA, individuals were assigned to classes by their highest 
posterior probabilities. Each subject was assigned to its definite latent class by the majority of the class 
memberships in 20 repeats. In addition, class membership was confirmed by visualizing sIgE 
prevalences in analogy to Figure 2. 
 
Supplemental tables  
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Table E1: Selection of study population 
 MAS PASTURE 
  Not included Included   Not included Included  
Variable  N % N % P  N % N % P 
Center 1 Berlin 316 49.84 278 40.88 0.0011 Austria 94 25.61 126 16.45 0.0003 
Center 2 Düsseldorf 52 8.20 109 16.03 0.0000 Switzerland 84 22.89 158 20.63 0.3847 
Center 3 Mainz 101 15.93 111 16.32 0.8466 France 46 12.53 157 20.50 0.0011 
Center 4 Freiburg 100 15.77 108 15.88 0.9567 Germany 94 25.61 160 20.89 0.0743 
Center 5 Munich 65 10.25 74 10.88 0.7106 Finland 49 13.35 165 21.54 0.0010 
High risk group  229 37.06 253 37.76 0.7936  -- -- -- -- -- 
Farming  -- -- -- -- --  153 41.69 377 49.22 0.0175 
Sex (female)  303 47.79 327 48.09 0.9144  161 49.39 369 48.30 0.7421 
Family history of allergic disease   309 50.08 345 50.88 0.7726  174 51.63 417 54.72 0.3431 
Maternal history of allergic disease  207 33.33 226 33.28 0.9850  110 30.05 261 34.07 0.1779 
High parental education  362 88.08 531 87.05 0.6264  307 87.46 701 91.87 0.0198 
At least 2 older siblings  76 11.99 89 13.11 0.5406  112 30.52 267 34.86 0.1475 
Breastfeeding in 1st year  547 88.37 612 90.94 0.1292  256 89.20 689 90.90 0.4048 
Environmental tobacco smoking  201 58.94 315 53.48 0.1062  32 17.88 56 8.20 0.0001 
Doctor’s diagnosed asthma at age 6  13 4.48 28 4.61 0.9305  4 2.27 36 5.28 0.0917 
Sensitized to any allergen at birth (CAP class 1)  -- -- -- -- --  31 12.20 81 11.91 0.9024 
Sensitized to any allergen at age 1 (CAP class 1)  28 13.66 90 16.70 0.3107  60 28.17 204 28.10 0.9841 
Sensitized to any allergen at age 2 (CAP class 1)  36 24.49 131 25.49 0.8063  -- -- -- -- -- 
Sensitized to any allergen at age 3 (CAP class 1)  29 24.79 133 26.71 0.6713  -- -- -- -- -- 
Sensitized to any allergen at age 4 (CAP class 1)  -- -- -- -- --  19 59.38 396 57.81 0.8609 
Sensitized to any allergen at age 5 (CAP class 1)  48 40.34 180 34.16 0.2026  -- -- -- -- -- 
Sensitized to any allergen at age 6 (CAP class 1)  42 42.42 160 37.74 0.3883  25 54.35 376 53.79 0.9415 
Given are absolute numbers and percentages (in brackets). P-values are derived from chi-square tests. The two columns represent the entire population and the analysis 
population with complete sIgE data for the selected time points. 
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Table E2: Model fit of latent class analysis 
Number of classes AIC Entropy 
MAS   
3 7384 (7361 - 7406) 0.96 (0.95 - 0.96) 
4 7172 (7151 - 7192) 0.95 (0.95 - 0.96) 
5 7064 (7044 - 7084) 0.97 (0.97 - 0.97) 
6 7067 (7047 – 7088) 0.96 (0.96 - 0.97) 
PASTURE   
3 14632 (14474 - 14791) 0.95 (0.94 - 0.96) 
4 14444 (14290- 14597) 0.92 (0.91- 0.94) 
5 14357 (14202 - 14511) 0.93 (0.92 - 0.94) 
6 14382 (14234 - 14530) 0.93 (0.91 - 0.95) 
Mean values of AIC and entropy are given with 95%-confidence intervals for 20 imputed data sets. 
 
Table E3: Prediction of latent sensitization classes by classical definitions of sensitization at age 6 – AUC of 
ROC analyses with 95% CIs 
Latent classes Any inhalant 
sensitization 
Any food 
sensitization 
MAS   
LC ‘Food’ 49.52 (44.34 - 54.69) 74.13 (68.58 - 79.68) 
LC ‘Seasonal’ 90.10 (86.74 - 93.45) 65.48 (58.92 - 72.04) 
LC ‘Mite’ 93.22 (91.55 - 94.89) 54.87 (47.00 - 62.73) 
LC ‘Severe atopy’ 90.70 (86.20 - 95.20) 94.89 (90.56 - 99.23) 
PASTURE   
LC ‘Cow’s milk’ 53.92 (49.40 - 58.43) 81.78 (78.74 - 84.82) 
LC ‘Food’ 57.85 (50.26 - 65.44) 91.98 (89.72 - 94.25) 
LC ‘Inhalant’ 77.49 (72.87 - 82.11) 55.45 (50.75 - 60.15) 
LC ‘Severe atopy’ 90.67 (87.17 - 94.16) 76.08 (68.24 - 83.91) 
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Figure E1: Distribution of latent classes across study centers 
 
Figure E2: Prediction of latent classes by classical definitions of sensitization at age 6 
 
The dots mark the sensitization statuses (from right to left: Unsensitized, CAP class 1-3) 
 
Figure E3: Associations of health conditions with latent classes and classical definitions of atopic sensitization 
at age 6 
 
* As there was no case of late onset wheeze in this LC, we calculated a conservative estimation of the odds ratio based 
on one case of late onset wheeze in this LC, which was simulated at random. 
Black point estimates with error bars mark the latent classes as reference, red the classical definitions as comparison. 
“Late onset wheeze” was defined as described at Depner M, Fuchs O, Genuneit J, Karvonen AM, Hyvarinen A, 
Kaulek V, et al. Clinical and epidemiologic phenotypes of childhood asthma. Am J Respir Crit Care Med 2014; 
189:129-38. 
 
Figure E4: Associations of latent classes with parental atopy 
 
Figure E5: Sensitivity analyses omitting single dimensions of LCA 
 
Figure E6: Comparing disease associations across all sensitivity analyses 
 
* As there was no case of lifetime asthma in this LC, we calculated a conservative estimation of the odds ratio based 
on one case of asthma in this LC, which was simulated at random. 
Black point estimates with error bars mark the latent classes as reference, red the classical definitions as comparison. 
 
Figure E7: Number of sensitizations to different allergen specificities across latent classes (CAP classes 1-3) 
 
Figure E8: Absolute sIgE levels at age 6 
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